BridgeBio Pharma, Inc. (BBIO) stock
BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$78.01+1.21 (+1.58%)
Close on Nov 18, 2026Market cap $15.20BP/E –Yield –
BridgeBio Pharma free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
BridgeBio Pharma's free cash flow for the twelve months ending Sep 30, 2026 was -$369.81M. For fiscal 2025 it was -$447.01M. The highest annual figure on record is -$40.95M in fiscal 2017.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$447.01M | – |
| FY2024 | Dec 31, 2024 | -$521.66M | – |
| FY2023 | Dec 31, 2023 | -$529.03M | – |
| FY2022 | Dec 31, 2022 | -$424.32M | – |
| FY2021 | Dec 31, 2021 | -$511.18M | – |
| FY2020 | Dec 31, 2020 | -$407.23M | – |
| FY2019 | Dec 31, 2019 | -$256.23M | – |
| FY2018 | Dec 31, 2018 | -$138.82M | – |
| FY2017 | Dec 31, 2017 | -$40.95M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$44.46M | – |
| Q2 FY2026 | Jun 30, 2026 | -$71.54M | – |
| Q1 FY2026 | Mar 31, 2026 | -$197.35M | – |
| Q4 FY2025 | Dec 31, 2025 | -$56.45M | – |
| Q3 FY2025 | Sep 30, 2025 | -$110.04M | – |
| Q2 FY2025 | Jun 30, 2025 | -$81.28M | -208.9% |
| Q1 FY2025 | Mar 31, 2025 | -$199.24M | – |
| Q4 FY2024 | Dec 31, 2024 | -$195.37M | – |
| Q3 FY2024 | Sep 30, 2024 | -$180.70M | – |
| Q2 FY2024 | Jun 30, 2024 | $74.65M | – |
| Q1 FY2024 | Mar 31, 2024 | -$220.23M | – |
| Q4 FY2023 | Dec 31, 2023 | -$125.25M | – |
| Q3 FY2023 | Sep 30, 2023 | -$145.66M | – |
| Q2 FY2023 | Jun 30, 2023 | -$113.78M | – |
| Q1 FY2023 | Mar 31, 2023 | -$144.33M | – |
| Q4 FY2022 | Dec 31, 2022 | -$94.04M | – |
| Q3 FY2022 | Sep 30, 2022 | -$135.92M | – |
| Q2 FY2022 | Jun 30, 2022 | -$32.86M | – |
| Q1 FY2022 | Mar 31, 2022 | -$161.49M | – |
| Q4 FY2021 | Dec 31, 2021 | -$136.43M | – |
| Q3 FY2021 | Sep 30, 2021 | -$128.02M | – |
| Q2 FY2021 | Jun 30, 2021 | -$94.00M | – |
| Q1 FY2021 | Mar 31, 2021 | -$152.73M | – |
| Q4 FY2020 | Dec 31, 2020 | -$98.41M | – |
| Q3 FY2020 | Sep 30, 2020 | -$132.23M | – |
| Q2 FY2020 | Jun 30, 2020 | -$88.20M | – |
| Q1 FY2020 | Mar 31, 2020 | -$88.40M | – |
| Q4 FY2019 | Dec 31, 2019 | -$77.95M | – |
| Q3 FY2019 | Sep 30, 2019 | -$50.38M | – |
| Q2 FY2019 | Jun 30, 2019 | -$68.33M | – |
| Q1 FY2019 | Mar 31, 2019 | -$59.57M | – |
| Q4 FY2018 | Dec 31, 2018 | -$47.16M | – |
See a number that looks wrong?